Compare BridgeBio Pharma Inc (BBIO) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs NetEase Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while NetEase Inc trades at $125.48 (market cap $83.89B). The key difference: NetEase Inc is far larger — about 5.1× BridgeBio Pharma Inc's market cap, and NetEase Inc pays a 2.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NTES | |
|---|---|---|
Market Cap | $16.61B | $83.89B |
Sector | Health | Media |
52-Week High | $90.17 | $159.34 |
52-Week Low | $47.29 | $109.26 |
Enterprise Value | $18.16B | $60.18B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
NTES trades at $132.22, up 1.43% today, with a bullish technical signal from moving averages and support near $131. The company reported Q1 2026 EPS of $2.53, beating estimates, and maintains strong profitability with a 29.84% net income margin. Recent news highlights upcoming Q2 2026 earnings on August 20, 2026, amid positive sentiment for Chinese tech stocks.
Outlook is positive with 82% analyst buy ratings and a 34.7% upside potential, though risks include earnings volatility and regulatory pressures. Revenue growth to $114.4B in 2026 and robust cash flow support valuation, but investors should monitor execution amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
